More physicians being sued by patients they’ve never treated
Do doctors ever have “legal duty of care” in such cases? An AMA education session explored the issue.
Related Articles
When AI Listens In: How Conversational Data Could Disrupt Medicine
When I began practicing medicine, use of the Internet or a smartphone could not have been imagined because neither existed.
Ozempic for addiction: How an elite rehab center is using GLP-1s to ‘obliterate’ all kinds of cravings
Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.
Dr. Fatima Rodriguez and Dr. C. Michael Gibson discuss: Atherosclerosis: Basic Concepts and Current Understanding – Clinical Trial Results
Sponsored by: Cleerly, Women as One and International Atherosclerosis
Zealand’s GLP-2 candidate shows early weight loss results
Zealand Pharma said that its obesity candidate that uses a unique mechanism led to notable weight loss in an early trial.
FDA Launches Agency-Wide AI Tool to Optimize Performance for the American People
FDA Launches Agency-Wide AI Tool
How to keep weight off after obesity drugs
Nature – Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or availability.
How to keep weight off after obesity drugs
Nature – Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or availability.
Metsera’s amylin drug shows early potential for substantial weight loss
Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial, the company said
Metsera’s amylin drug shows early potential for substantial weight loss
Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial, the company said
Great debate: default duration of dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndrome should be 12 months
In the 1980s, atherothrombosis was definitively established as the most prevalent mechanism underlying acute coronary syndromes (ACS).1,2 In the 1990s, sin